scholarly journals 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study

2017 ◽  
Vol 137 (5) ◽  
pp. S45 ◽  
Author(s):  
Y.H. Kim ◽  
S. Whittaker ◽  
S.M. Horwitz ◽  
M. Duvic ◽  
R. Dummer ◽  
...  
Keyword(s):  
T Cell ◽  
Standard Therapy ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Phase 3

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

The Lancet ◽  
2017 ◽  
Vol 390 (10094) ◽  
pp. 555-566 ◽  
Author(s):  
H Miles Prince ◽  
Youn H Kim ◽  
Steven M Horwitz ◽  
Reinhard Dummer ◽  
Julia Scarisbrick ◽  
...  
Keyword(s):  
T Cell ◽  
Multicentre Trial ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Open Label ◽  
Phase 3

scholarly journals Our first experiences with brentuximab vedotin in the treatment of cutaneous T-cell lymphoma

2019 ◽  
Vol 95 (3) ◽  
pp. 129-135
Author(s):  
József Szakonyi ◽  
◽  
Veronika Tóth ◽  
Béla Tóth ◽  
Ágota Szepesi ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

scholarly journals Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

The Lancet ◽  
2019 ◽  
Vol 393 (10168) ◽  
pp. 229-240 ◽  
Author(s):  
Steven Horwitz ◽  
Owen A O'Connor ◽  
Barbara Pro ◽  
Tim Illidge ◽  
Michelle Fanale ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Brentuximab Vedotin ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Phase 3 ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document